Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Adult Vaccination Ecosystem in IndiaRelease Date:Quality Improvement Vaccines India Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic DermatitisRelease Date:Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology All Enhancing HCP Education in Maternal VaccinationRelease Date:Education Vaccines Saudi Arabia Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology All Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic DiseasesRelease Date:Education Inflammation & Immunology USA B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology USA Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia AreataRelease Date:Education Inflammation & Immunology USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi ArabiaRelease Date:Research Vaccines Saudi Arabia Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing EquityRelease Date:Education Inflammation & Immunology Australia Title Grant Type Focus Area Country Application Due Date Optimizing Androgen Deprivation Therapy (ADT) in Advanced Prostate CancerEducation Oncology USA Optimizing Biomarker-Directed Therapy in Metastatic Colorectal CancerRelease Date:Partner: The National Comprehensive Cancer Network®, Fight Colorectal CancerQuality Improvement Oncology USA Addressing the Needs of Patients with Mental Health Issues and Dermatological Inflammatory ConditionsRelease Date:Quality Improvement Inflammation & Immunology Canada Quality Improvement Grants to Improve Identification and Management of Patients with ATTR-CMRelease Date:Quality Improvement Rare Disease Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) ResearchRelease Date:Research Rare Disease USA Improving Treatment Environment and Survivorship for Multiple MyelomaRelease Date:Education Oncology Japan Improving Treatment Environment and Survivorship for LeukemiaRelease Date:Education Oncology Japan Advances in the Management of Ulcerative Colitis (UC) (Europe, Canada, Japan, South Korea, Australia, New Zealand, Israel)Release Date:Education Inflammation & Immunology All Increasing Awareness and Understanding of Transthyretin Cardiomyopathy (ATTR-CM)Release Date:Education Rare Disease USA Shared Decision-Making (SDM) for Patient Quality of Life in Cancer Treatment and Improving Access to BiologicsRelease Date:Education Oncology Japan Improvement of Treatment Environment of Immuno-Oncology Therapy for Urothelial CancerRelease Date:Quality Improvement Oncology Japan Optimizing the management of mBC HER2-patients / OncologyRelease Date:Quality Improvement Oncology Italy